The cyclooxygenase-2 pathway as a target for treatment or prevention of cancer

Bibliography

• VANE JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature (1990) 231:232–235.
   Google Scholar
• GUPTA RA, DUBOIS RN: Colorectal cancer and the cyclooxygenase pathway. Nat. Rev Cancer (2001) 1:11–21.
   PubMed Web of Science ®Google Scholar
• ••An excellent review of role of COX incolorectal cancer.
   Google Scholar
• MARNETT LJ: Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res. (1992) 52:5575–5589.
   PubMed Web of Science ®Google Scholar
• MARNETT LJ, DUBOIS RN: COX-2: a target for colon cancer prevention. Ann. Rev Pharmacol. Toxicol. (2002) 42:55–80.
   PubMed Web of Science ®Google Scholar
• NARUMIYA S, SUGIMOTO Y, USHIKUBI F: Prostanoid receptors: structures, properties, and functions. Physiol. Rev. (1999) 79:1193–1226.
   PubMed Web of Science ®Google Scholar
• XIE W, CHIPMAN J, ROBERTSON D, ERIKSON R, SIMMONS D: Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc. Nati Acad. ScL USA (1991) 88:2692–2696.
   PubMed Web of Science ®Google Scholar
• KUJUBU DA, FLETCHER BS, VARNUM BC, LIM RW, HERSCHMAN HR: TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J. Biol. Chem. (1991) 266:12866–12872.
   PubMed Web of Science ®Google Scholar
• O'BANION MK, SADOWSKI HB, WINN V, YOUNG DA: A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. Biol Chem. (1991) 266:23261–23267.
   Web of Science ®Google Scholar
• O'BANION MK, WINN VD, YOUNG DA: cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc. Nati Acad. Sci. USA (1992) 89(11):4888–4892.
   PubMed Web of Science ®Google Scholar
• SMITH WL, DEWITT DL, GARAVITO RM: Cyclooxygenases: structural, cellular, and molecular biology. Ann. Rev Biochem. (2000) 69:145–182.
   PubMed Web of Science ®Google Scholar
• WADLEIGH DJ, REDDY ST, KOPP E, GHOSH S, HERSCHMAN HR: Transcriptional activation of the cyclooxygenase-2 gene in endotwdn-treated RAW 264.7 macrophages. J. Biol Chem. (2000) 275(9):6259–6266.
   PubMed Web of Science ®Google Scholar
• MARNETT LJ, KALGUTKAR AS: Cyclooxygenase 2 inhibitors: discovery, selectivity and the future. Trends Pharmacol. Sci (1999) 20(11):465–469.
   PubMed Web of Science ®Google Scholar
• KURUMBAIL RG, STEVENS AM, GIERSE JK et al.: Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature (1996) 384:644–648.
   PubMed Web of Science ®Google Scholar
• LAINE L, HARPERS, SIMON T et al: A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology (1999) 117:776–783.
   PubMed Web of Science ®Google Scholar
• EMERY P, ZEIDLER H, KVIEN TK et al.:Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet (1999) 354:2106–2111.
   PubMed Web of Science ®Google Scholar
• BOMBARDIER C, LAINE L, REICIN A et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl. I Med. (2000) 343:1520–1528.
   PubMed Web of Science ®Google Scholar
• •Patient study that showed safety profile of rofecoxib.
   Google Scholar
• DANNENBERG AJ, ALTORKI NK, BOYLE JO, LIN DT, SUBBARAMAIAH K: Inhibition of cyclooxygenase-2: an approach to preventing cancer of the upper aerodigestive tract. Ann. NY Acad. Sci (2001) 952:109–115.
   PubMed Web of Science ®Google Scholar
• SHAO J, SHENG H, INOUE H, MORROW JD, DUBOIS RN: Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells.' Biol. Chem. (2000) 275:33951–33956.
   Web of Science ®Google Scholar
• ACHIWA H, YATABE Y, HIDA T et al.: Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin. Cancer Res. (1999) 5:1001–1005.
   PubMed Web of Science ®Google Scholar
• KHURI FR, WU H, LEE JJ et al.: Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin. Cancer Res. (2001) 7(4):861–867.
   PubMed Web of Science ®Google Scholar
• BENNETT A, DEL TACCA M, STAMFORD IF, ZEBRO T: Prostaglandins from tumours of human large bowel. Br. Surg. (1977) 35:882–884.
   Google Scholar
• GIOVANNUCCI E, RIMM EB, STAMPFER MJ et al.: Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann. Intern. Med. (1994) 121:241–246.
   PubMed Web of Science ®Google Scholar
• DEMPKE W RC, GROTHEY A, SCHMOLL HJ: Cyclooxygenase-2: a novel target for cancer chemotherapy? Cancer Res. Clin. Oncol. (2001) 127:411–417.
   PubMed Web of Science ®Google Scholar
• LIU HL, CHANG SH, NARKO K et al.:Over-expression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J. Biol. Chem. (2001) 276:18563–18569.
   PubMed Web of Science ®Google Scholar
• OSHIMA M, DINCHUK JE, KARGMAN SL et al.: Suppression of intestinal polyposis in APC-716 knockout mice by inhibition of prostaglandin endoperwdde synthase-2 (COX-2). Cell (1996) 87:803–809.
   PubMed Web of Science ®Google Scholar
• ••The first study to show direct geneticevidence that COX-2 is implemented in intestinal polyp formation and carcinogenesis.
   Google Scholar
• WILLIAMS CS, TSUJII M, REESE J, DEY SK, DUBOIS RN: Host cyclooxygenase-2 modulates carcinoma growth. j. Clin. Invest. (2000) 105:1589–1594.
   PubMed Web of Science ®Google Scholar
• •A study that provides genetic evidence that COX-2 in the tumour stroma can promote carcinoma cell growth.
   Google Scholar
• BANDYOPADHYAY GK, IMAGAWA W, WALLACE D et al.: Linoleate metabolites enhance the in vitro proliferative response of mouse mammary epithelia cells to epidermal growth factors. J. Biol. Chem. (1987) 262:2750–2756.
   PubMed Web of Science ®Google Scholar
• MAJIMA M, HAYASHI I, MURAMATSU M et al.: Cyclo-oxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants. Br. Pharmacol. (2000) 130(3):641–649.
   PubMed Web of Science ®Google Scholar
• MAJIMA M, ISONO M, IKEDA Y et al.: Significant roles of inducible cyclooxygenase (COX)-2 in angiogenesis in rat sponge implants. fpn. Pharmacol. (1997) 75(2):105–114.
   Web of Science ®Google Scholar
• GATELY S: The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev (2000) 19:19–27.
   PubMed Web of Science ®Google Scholar
• DANIEL TO, LIU H, MORROW JD, CREWS BC, MARNETT LJ: Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res. (1999) 59:4574–4577.
   PubMed Web of Science ®Google Scholar
• SUBBARAMAIAH K, ALTORKI N, CHUNG WJ et al.: Inhibition of cyclooxygenase-2 gene expression by p53. Biol. Chem (1999) 274(16):10911–10915.
   Web of Science ®Google Scholar
• LEUNG WK, TO KF, NG YP et al.: Association between cyclo-oxygenase-2 overexpression and missense p53 mutations in gastric cancer. Br. J. Cancer (2001) 84(3):335–339.
   PubMed Web of Science ®Google Scholar
• ADAM L, MAZUMDAR A, SHARMA T, JONES TR, KUMAR R: A three-dimensional and temporo-spatial model to study invasiveness of cancer cells by heregulin and prostaglandin E2. Cancer Res. (2001) 61(1):81–87.
   PubMed Web of Science ®Google Scholar
• SHENG H, SHAO J, WASHINGTON MK, DUBOIS RN: Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. Biol. Chem (2001) 276:18075–18081.
   Web of Science ®Google Scholar
• TSUJII M, DUBOIS RN: Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperwdde synthase-2. Cell (1995) 83:493–501.
   PubMed Web of Science ®Google Scholar
• ••The first study to document that pro-oncogenic pathways can be activated by COX-2 overexpression.
   Google Scholar
• TSUJII M, KUWANO S, DUBOIS RN: Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc. Natl. Acad. Sci. USA (1997) 94:3336–3340.
   PubMed Web of Science ®Google Scholar
• YOU Z, SAIMS D, CHEN S et al: Wnt signaling promotes oncogenic transformation by inhibiting c-Myc-induced apoptosis. J. Cell Biol. (2002) 157(3):429–440.
   PubMed Web of Science ®Google Scholar
• •Study that explains COX-2's role in the Wnt pathway.
   Google Scholar
• YOST CM, TORRES M, MILLER JR et al.: The axis-inducing activity stability, and subcellular distributions of beta-catenin is regulated in Xenopus embryos by glycogen synthase 3. Genes Dev. (1996) 10:1443–1454.
   PubMed Web of Science ®Google Scholar
• IKEDA S, KISHIDA S, YAMAMOTO H et al.: Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3B and B-catenin and promotes GSK- 3B-dependent phosphorylation of B-catenin. EMBO J. (1998) 17:1371–1384.
   PubMed Web of Science ®Google Scholar
• POLAKIS P: Wnt signaling and cancer. Genes Dev. (2000) 14:1837–1851.
   PubMed Web of Science ®Google Scholar
• PEIFER M, POLAKIS P: Wnt signaling in oncogenesis and embryogenesis - a look outside the nucleus. Science (2000) 287:1606–1609.
   PubMed Web of Science ®Google Scholar
• BIENZ M, CLEVERS H: Linking colorectal cancer to Wnt signaling. Cell (2000) 103:311–320.
   PubMed Web of Science ®Google Scholar
• GAT U, DASGUPTA R, DEGENSTEIN L, FUCHS E: Be novo hair follicle morphogenesis and hair tumors in mice expressing a truncated B-catenin in skin. Cell(1998) 95:605–614.
   PubMed Web of Science ®Google Scholar
• LANGMAN M, BOYLE P: Chemoprevention of colorectal cancer. Gut (1998) 43:578–585.
   PubMed Web of Science ®Google Scholar
• WADDELL WR, LOUGHRY RW: Sulindac for polyposis of the colon. J. &mg. Oncol (1983) 24:83–87.
   Web of Science ®Google Scholar
• ••The first clinical observation that NSAIDscould cause the regression of intestinal polyps.
   Google Scholar
• THUN MJ, NAMBOODIRI MM, HEATH CWJ: Aspirin use and reduced risk of fatal colon cancer. N Engl. J. Med. (1991) 325: 1593–1596.
   Google Scholar
• ••The largest prospective population-basedstudy that showed a correlation between NSAID use and a reduction in relative risk of colon cancer.
   Google Scholar
• DUBOIS RN, GIARDIELLO FM, SMALLEY WE: Nonsteroidal anti-inflammatory drugs, eicosanoids and colorectal cancer prevention. Gastroenterol Gin. North Am. (1996) 25:773–791.
   PubMed Web of Science ®Google Scholar
• SMALLEY W, DUBOIS RN: Colorectal cancer and non steroidal anti-inflammatory drugs. Adv. Phannacol (1997) 39:1–20.
   PubMedGoogle Scholar
• KINZLER KW, NILBERT MC, VOGELSTEIN B et al.: Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. Science (1991) 251(4999):1366–1370.
   PubMed Web of Science ®Google Scholar
• STEINBACH G, LYNCH PM, PHILLIPS RKS et al.: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl. J. Med. (2000) 342:1946–1952.
   PubMed Web of Science ®Google Scholar
• ••The first study to show that a selectiveCOX-2 inhibitor could cause polyp regression in patients with FAP.
   Google Scholar
• SILVERSTEIN FE, FAICH G, GOLDSTEIN JL et al.: Gastrointestinal toxicity with celecoxib versus nonsteroidal anti- inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA (2000) 284(10):1247–1255.
   PubMed Web of Science ®Google Scholar
• SINGH G: Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am. J. Med. (1998) 105:31S–38S.
   Google Scholar
• PAULSON SK, HRIBAR JD, LIU NW et al.: Metabolism and excretion of [(14)C]celecoxib in healthy male volunteers. Drug Metab. Dispos. (2000) 28:308–314.
   PubMed Web of Science ®Google Scholar
• DEPRE M EE, VAN HECKEN A, DE LEPELEIRE I et al.: Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans. Eur. Clin. Pharmacol (2000) 56:167–174.
   Web of Science ®Google Scholar
• ZHAO SZ BT, WHELTON A, VON ALLMEN H, HENDERSON SC: Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2 specific inhibitors. Am. J. Manage. Care (2002) 8:S414–S427.
   PubMed Web of Science ®Google Scholar
• •Large patient population study documenting the risk of heart complications in NSAID users.
   Google Scholar
• ZHAO SZ BT, WHELTON A, VON ALLMEN H, HENDERSON SC: Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs an COX-2 specific inhibitors. Am. J. Manage. Care (2002) 8:S401–S413.
   PubMed Web of Science ®Google Scholar
• WHELTON A, WHITE WB, BELLO AE et al.: Effects of celecoxib and rofecoxib on blood pressure and edema in patients greater than 65 years of age with systemic hypertension and osteoarthritis. Am. J. Cardiol (2002) 90:959–963.
   PubMed Web of Science ®Google Scholar
• •Clinical study showing changes in blood pressure and oedema after celecoxib and rofecoxib use.
   Google Scholar
• ZHANG X, MORHAM SG, LANGENBACH R, YOUNG DA: Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J. Exp. Med. (1999) 190:445–450.
   PubMed Web of Science ®Google Scholar
• HANIF R, PITTAS A, FENG Y et al.: Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem. Pharm. (1996) 52:237–245.
   PubMed Web of Science ®Google Scholar
• JACOBY RF, SEIBERT K, COLE CE, KELLOFF G, LUBET RA: The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res. (2000) 60(18):5040–5044.
   PubMed Web of Science ®Google Scholar
• HE TC, CHAN TA, VOGELSTEIN B, KINZLER KW: PPARd is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Ce//(1999) 99:335–345.
   Google Scholar
• ZHANG L, YU J, PARK BH, KINZLER KW, VOGELSTEIN B: Role of BAX in the apoptotic response to anticancer agents. Science (2000) 290(5493):989–992.
   PubMed Web of Science ®Google Scholar
• TORRANCE CJ, JACKSON PE, MONTGOMERY E et al: Combinatorial chemoprevention of intestinal neoplasia. Nat. Med. (2000) 6:1024–1028.
   PubMed Web of Science ®Google Scholar
• •This group showed that treatment of ApcMin mice with sulindac and an ERBB inhibitor leads to complete suppression of polyp formation.
   Google Scholar
• KOKI AT HJ, WOERNER BM, ZWEIFEL B et al.: Characterization of COX-2 expression and HER/neu in human breast, colon, and prostate cancer. Proceedings of the 1 Ith NCI EORTC AACR Symposium (2000).
   Google Scholar
• HOWE LR, SUBBARAMAIAH K, BROWN AMC, DANNENBERG AJ: Cyclooxygenase-2: a target for the prevention of breast cancer. Endocr. Relat. Cancer (2001) 8:97–114.
   PubMed Web of Science ®Google Scholar
• MANN M, SHENG H, SHAO J et al.: Targeting cyclooxygenase 2 and her-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology(2001) 120: 1713–1719.
   Google Scholar
• UN EH EA: Celecoxib attenuated capecitabine induced hand-and-foot syndrome (HFS) and diarrhea and improved time to tumor progression in metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. (2002) 21:101.
   Google Scholar